55X_ROI_Q1_2026
Nov 20, 7:49 PM
$SLS $MRK $ABBV Ceo transcript estimating Cr2 market Scope.
Revenue could top
$10B Per YEAR --- Just for AML Remission Maintenance
Will set record patient uptake rates - 75% is current standard w new drugs - 2x 3x OS Advantage / Pristine Safety 100% QoL /in home Sub Q
• 12,500 CR2/3 Patients
•
$500K Per Patient
•
$6.25B TAM Just for the Initial P3 Setting
75% uptake --
$4.7B in Actual Revenue Just from the Cr2/3 setting
that
$4B alone is worth 6x -8x multiple
••
$24B -
$28B
215M shares Float /
$24B
$111 Per SLS SHARE * - includes Latest Offering
- again just Cr2/3 - which is inaccurate, as GPS P3 MOS for Cr2/ and LATER - is as good as Standard of Care / Onureg in CR1
GPS will Also be Valued for this Much Larger Indication
50,000 AML CR1 Patients Each YEAR
--- the math is boggling. the current discounted share price is an aberration.
$MRNA $XBI
0 replies